TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30877658
Drug: 6α‐methylprednisolone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6α‐methylprednisolone acetate (MA) 40 mg
Study: 30877658
Drug: triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: triamcinolone acetonide (TA) 40 mg
Study: 25131073
Drug: rATG (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: rATG (multiple doses starting intraoperatively)
Study: 25131073
Drug: ALEM (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALEM (30 mg intraoperatively)
Study: 20817153
Drug: CBT +
Normalized name: Cannabidiol
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBT + DCS (25 or 50 mg)
Study: 9505188
Drug: ceftibuten 400
Normalized name: ceftibuten 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftibuten 400 mg once daily
Study: 9505188
Drug: clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clarithromycin 500 mg twice daily
Study: 8540613
Drug: Neoadjuvant combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant combination therapy with flutamide and an LHRH agonist for 3 months
Study: 24320906
Drug: Herbal dentifrice
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal dentifrice (Hi Ora K, The Himalaya Drug Company)
Study: 24320906
Drug: Placebo dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dentifrice (The Himalaya Drug Company)
Study: 20199402
Drug: C (bathing
Approvals — FDA: no, EMA: no, PMDA: no
Description: C (bathing and cream)
Study: 20199402
Drug: WG +
Normalized name: Warfarin Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: WG + C (bathing with wash gel plus cream)
Study: 11277374
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg per day for up to 9 days in a reducing schedule)
Study: 9973793
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (group A)
Study: 9973793
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic prophylaxis (group B)
Study: 7603075
Drug: Amlodipine (11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (11 mg intravenous dose)
Study: 29155973
Drug: Tapering MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering MTX (double-blind)
Study: 22824474
Drug: AS03A-adjuvanted A/California/7/2009
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03A-adjuvanted A/California/7/2009 H1N1 vaccine (1.9 μg HA) administered at 21 days
Study: 22824474
Drug: AS03A-adjuvanted A/California/7/2009
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03A-adjuvanted A/California/7/2009 H1N1 vaccine (1.9 μg HA) administered at 21 days or 6 months
Study: 30104006
Drug: CTRT (RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTRT (RT + weekly cisplatin), n = 94
Study: 26632091
Drug: IPX066 (carbidopa-levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX066 (carbidopa-levodopa extended-release capsules)
Study: 25634565
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV methylprednisolone (2 mg/kg loading dose, 1 mg/kg/d continuous infusion on days 1‐7, tapered on days 8‐14)
Study: 24231627
Drug: Pemetrexed alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed alone (500 mg/m2)
Study: 24231627
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2) with cetuximab
Study: 24231627
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2) alone
Study: 3341247
Drug: Multivitamin and
Normalized name: Multivitamin and Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin and mineral supplement
Study: 1764940
Drug: Insertion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insertion of NORPLANT implants with scalpel
Study: 1764940
Drug: Insertion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insertion of NORPLANT implants without scalpel
Study: 28552382
Drug: Icatibant 30
Normalized name: icatibant 30 MG in 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icatibant 30 mg
Study: 19542866
Drug: TDF/FTC 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC 300 mg/200 mg with lopinavir/ritonavir 800 mg/200 mg
Study: 19542866
Drug: ABC/3TC 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABC/3TC 600 mg/300 mg with lopinavir/ritonavir 800 mg/200 mg
Study: 15147545
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation (leuprolide and chlormadinone acetate) for 3 months followed by radical prostatectomy and subsequent adjuvant endocrine therapy (leuprolide alone)
Study: 15147545
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by 3-month androgen deprivation (leuprolide and chlormadinone acetate) and subsequent adjuvant endocrine therapy (leuprolide alone)
Study: 15147545
Drug: Preoperative androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative androgen deprivation in subpopulation with PSA < 35.6 ng/mL and clinical stage B or C cancers
Study: 11120904
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (1 mg/kg/day for three months, then 10 mg/day for three months)
Study: 10092565
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural treatment (n = 56)
Study: 7407516
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate and propranolol (380 mg/day) while not smoking
Study: 27456328
Drug: Complex intervention
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex intervention involving GPs and HCAs conducting checklist-based interviews and medication reconciliation with the aid of a CDSS.
Study: 19552963
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER 3-12 mg/day
Study: 12692056
Drug: Interferon 3
Normalized name: interferon beta-1b 0.3 MG [Betaseron]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon 3 MU daily for the first four weeks and subsequently 3 MU three times a week, and ribavirin as in regimen A
Study: 10726917
Drug: Control (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (insulin infusion using euglycemic clamp protocol for 240 minutes at a rate of 40 mU/m2/min for young and 34 mU/m2/min for old)
Study: 10726917
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) coinfused with insulin
Study: 10726917
Drug: Control (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (insulin infusion)
Study: 1335641
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine, strain HM175, 360 ELISA units (El.U) on days 0 and 28
Study: 1335641
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine, strain HM175, 720 ELISA units (El.U) on days 0 and 14 (abbreviated schedule)
Study: 30151212
Drug: Mirogabalin 50
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 50 and 75 mg single dose
Study: 30049303
Drug: Mirogabalin 15
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 15 mg
Study: 30151212
Drug: Mirogabalin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirogabalin (various doses)
Study: 26996385
Drug: Cyclophosphamide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide + Veliparib (60 mg daily)
Study: 26996385
Drug: Cyclophosphamide alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide alone (50 mg once daily)
Study: 15892594
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin 40mg once daily
Study: 12699438
Drug: GHRH (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (1 micro g/kg)
Study: 11220764
Drug: Full-dose PRP-T
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose PRP-T Hib vaccine
Study: 11220764
Drug: Half-dose PRP-T
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose PRP-T Hib vaccine
Study: 11220764
Drug: Half-dose PRP-T
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose PRP-T Hib vaccine combined with DTP
Study: 11220764
Drug: One-third-dose PRP-T
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-third-dose PRP-T Hib vaccine combined with DTP
Study: 23660990
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg droperidol
Study: 10425409
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg droperidol
Study: 6815974
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg morphine
Study: 6815974
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg morphine
Study: 1486261
Drug: 1,3,7-trimethylxanthine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,3,7-trimethylxanthine (800 mg in caffeinated coffee)
Study: 27930531
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline solution)
Study: 18222357
Drug: Bezafibrate therapy
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate therapy
Study: 1623913
Drug: Indomethacin (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (dosage not specified)
Study: 25462201
Drug: Unilateral TAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral TAP block with 30 cc of 0.25% bupivacaine with 3 mcg/mL epinephrine
Study: 30487248
Drug: GAD gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GAD gene therapy delivered into the subthalamic nucleus (STN)
Study: 23737536
Drug: Quarter-dose DSA
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarter-dose DSA program
Study: 8668669
Drug: Ketoprofen 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 3% gel applied to the knee
Study: 3048225
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg scopolamine hydrobromide
Study: 15127155
Drug: Linac radiosurgery
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linac radiosurgery (median dose 20 Gy)
Study: 2368961
Drug: Inhaled furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled furosemide (3.75 mg/ml for 8 min)
Study: 9150838
Drug: Inhaled furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled furosemide
Study: 351664
Drug: Medication and
Normalized name: CVS Health Medication and Topical Refill Pouch KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication and leaderless group
Study: 28925059
Drug: Amorolfine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorolfine 5% nail lacquer (once-weekly application)
Study: 28925059
Drug: Ciclopirox 8%
Normalized name: CICLOPIROX 8% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclopirox 8% nail lacquer (once-daily application)
Study: 28925059
Drug: Urea 40%
Normalized name: UREA 40% CREAM
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea 40% ointment/bifonazole 1% cream combination (once-daily application)
Study: 28925059
Drug: Urea 40%
Normalized name: UREA 40% CREAM
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea 40% ointment
Study: 23586591
Drug: Bifonazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole 1% cream
Study: 18294021
Drug: Intramuscular risperidone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular risperidone, 25 mg every other week
Study: 10924665
Drug: Bilateral ECT
Normalized name: ECT-001 expanded cord blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ECT (all dosage groups)
Study: 1954636
Drug: Idarubicin (IDA)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (IDA) 12 mg/m2 daily for 3 days + Cytosine arabinoside 200 mg/m2 daily for 5 days
Study: 1954636
Drug: Daunorubicin (DNR)
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin (DNR) 50 mg/m2 daily for 3 days + Cytosine arabinoside 200 mg/m2 daily for 5 days
Study: 6908875
Drug: Long-term gestagen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term gestagen therapy (100 mg medrogestone or medroxyprogesterone acetate daily for 2-5 years)
Study: 30479087
Drug: Paclitaxel-based hyperthermic
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-based hyperthermic intraperitoneal chemotherapy (HIPEC) with 175 mg/m² for 90 minutes after interval debulking surgery (IDS)
Study: 24882554
Drug: Sunitinib 50mg
Normalized name: sunitinib 50 MG
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 50mg daily (4 weeks on, 2 weeks off)
Study: 16500662
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Simvastatin 20mg and Losartan 100mg)
Study: 31421426
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LMWH therapy)
Study: 26986096
Drug: Dexlansoprazole MR-based
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR-based triple therapy (60 mg once daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily)
Study: 26986096
Drug: Rabeprazole-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole-based triple therapy (20 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily)
Study: 26986096
Drug: Dexlansoprazole MR-based
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR-based triple therapy
Study: 25201463
Drug: Mg group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg group
Study: 20447229
Drug: Drug dependence
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug dependence treatment trials
Study: 20447229
Drug: Trials comparing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trials comparing widely different treatments
Study: 18490084
Drug: Infants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants with apnea who participated in the vaccine trial
Study: 18490084
Drug: Infants from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants from the vaccine trial control group
Study: 7571769
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (2 x 40 mg)
Study: 7571769
Drug: Nisoldipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (2 x 10 mg)
Study: 21487851
Drug: University of
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: University of Wisconsin solution (UW)
Study: 30687986
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control group (WLC) with full access to treatment as usual
Study: 15165648
Drug: Family‐Focused Grief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family‐Focused Grief Therapy (FFGT)
Study: 8119064
Drug: Short-duration chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-duration chemotherapy
Study: 7981389
Drug: Long-duration chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-duration chemotherapy
Study: 2662740
Drug: APSAC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: APSAC treatment
Study: 236337
Drug: pipradrol‐vitamin (Alertonic)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pipradrol‐vitamin (Alertonic) elixir
Study: 356078
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment
Study: 29231341
Drug: Diane-35 (western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane-35 (western medication)
Study: 25331845
Drug: Unilateral baroreflex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral baroreflex activation therapy (BAT)
Study: 25331845
Drug: Bilateral baroreflex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral baroreflex activation therapy (BAT)
Study: 21471085
Drug: Vardenafil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (5 mg twice daily)
Study: 17418218
Drug: Roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 300 mg daily for 28 days
Study: 11985388
Drug: Acetazolamide 500
Normalized name: acetazolamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 500 mg daily
Study: 27018419
Drug: Gabapentin 250
Normalized name: GABAPENTIN 250MG/5ML SOLN,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 250 mg
Study: 20819324
Drug: Acetaminophen (4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4000 mg/day)
Study: 8002646
Drug: Prednisone therapy
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone therapy
Study: 12804077
Drug: 7.5 g
Normalized name: glucose 15 GM per 37.5 GM Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 g of aromatics inunction
Study: 11112238
Drug: Raloxifene 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 30 mg
Study: 9364981
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of antiprothrombin antibodies
Study: 17891382
Drug: Bromocriptine (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (dopamine D2 agonist)
Study: 17891382
Drug: Haloperidol (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (dopamine D2 antagonist)
Study: 10483801
Drug: Saline (S)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (S) containing 100 mmol of NaCl x l(‐1)
Study: 8709370
Drug: Intravesical capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical capsaicin (10 microM, twice weekly for 1 month)
Study: 31246370
Drug: Combined ACT
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ACT + DBT + FAP therapy group (n = 23)
Study: 20191935
Drug: Gaboxadol 10
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol 10 mg
Study: 19094161
Drug: Zolpidem 5
Normalized name: zolpidem 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 5 mg (active control)
Study: 9251634
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (sulphasalazine 2 g/day, methotrexate 7.5 mg/week, prednisolone initially 60 mg/day tapered to 7.5 mg/day)
Study: 22369393
Drug: Lactobacillus (510
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus (510 mg/day for a median of 4.0 days)
Study: 16192835
Drug: LY354740 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY354740 (100 or 200 mg)
Study: 16192835
Drug: Paroxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (60 mg)
Study: 9790491
Drug: Intensive individual
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive individual CBT administered by a skilled therapist
Study: 2562096
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including alkalinized solutions)
Study: 31481106
Drug: Riociguat (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat (maximum of 2.5 mg three times daily)
Study: 28820780
Drug: Exenatide (1‐h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (1‐h bolus of 0.05 µg/min followed by a constant infusion of 0.025 µg/min)
Study: 28820780
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (control group)
Study: 19454870
Drug: Lacosamide 200
Normalized name: lacosamide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide 200 mg/d
Study: 25263393
Drug: Rifampicin 450
Normalized name: Rifampicin 450 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 450 mg/day for 7 days
Study: 9297650
Drug: Tannin‐fluoride preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tannin‐fluoride preparation
Study: 2942167
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (IB) 120 micrograms delivered by a metered dose inhaler (MDI)
Study: 30982549
Drug: New-generation drug-eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: New-generation drug-eluting stents (DES)
Study: 27026339
Drug: Umeclidinium (UMEC)
Normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium (UMEC) 15.6, 31.25, 62.5, 125, and 250 mcg once daily; 15.6 and 31.25 mcg twice daily
Study: 26293451
Drug: Aliskiren add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren add-on therapy to ARB
Study: 17056122
Drug: Valproate (500-1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (500-1500 mg/day)
Study: 17056122
Drug: Olanzapine (7.5-15.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (7.5-15.0 mg/day)